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Abstract 
Background: The EuroQol EQ-5D is one of the most widely researched and applied patient-reported outcome 
measures worldwide. The original EQ-5D-3L and more recent EQ-5D-5L include three and five response categories 
respectively. Evidence from healthy and sick populations shows that the additional two response categories improve 
measurement properties but there has not been a concurrent comparison of the two versions in patients with low 
back pain (LBP).
Methods: LBP patients taking part in a multicenter randomized controlled trial of lumbar total disc replacement and 
conservative treatment completed the EQ-5D-3L and 5L in an eight-year follow-up questionnaire. The 3L and 5L were 
assessed for aspects of data quality including missing data, floor and ceiling effects, response consistency, and based 
on a priori hypotheses, associations with the Oswestry Disability Index (ODI), Pain-Visual Analogue Scales and Hopkins 
Symptom Checklist (HSCL-25).
Results: At the eight-year follow-up, 151 (87%) patients were available and 146 completed both the 3L and 5L. Levels 
of missing data were the same for the two versions. Compared to the EQ-5D-5L, the 3L had significantly higher floor 
(pain discomfort) and ceiling effects (mobility, self-care, pain/discomfort, anxiety/depression). For these patients the 
EQ-5D-5L described 73 health states compared to 28 for the 3L. Shannon’s indices showed the 5L outperformed the 
3L in tests of classification efficiency. Correlations with the ODI, Pain-VAS and HSCL-25 were largely as hypothesized, 
the 5L having slightly higher correlations than the 3L.
Conclusion: The EQ-5D assesses important aspect of health in LBP patients and the 5L improves upon the 3L in this 
respect. The EQ-5D-5L is recommended in preference to the 3L version, however, further testing in other back pain 
populations together with additional measurement properties, including responsiveness to change, is recommended.
Trial registration: retrospectively registered: https:// clini caltr ials. gov/ ct2/ show/ NCT01 704677.
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Background
The EQ-5D is one of the most widely tested and applied 
patient-reported outcome measures (PROM) world-
wide. It has been translated into over 170 languages and 
national scoring algorithms exist for over 20 countries [1, 
2]. Widespread application includes clinical and health 
services research, economic evaluation based on cost per 
quality adjusted life years (QALY) [3] and more recently, 
national quality measurement. The latter includes the 
National Health Service’s Patient Reported Outcome 
Measures (PROMs) programme for England [2] and 
medical registers in Norway and Sweden where it is the 
most widely used PROM [4, 5]. The EQ-5D is one of the 
mostly widely used PROMS for patients with low back 
pain (LBP) across these applications [3–8].
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The EQ-5D-3L version includes five dimensions, or 
important aspects of health (mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression), with 
three levels (no problem, some problems, severe prob-
lems) [2]. It is thus highly acceptable to patients and fea-
sible for application where a short-form general measure 
of health is required. With the aim of improving the pre-
cision and responsiveness to change, the charity which 
owns the EQ-5D, the EuroQol Foundation, has developed 
the EQ-5D-5L [9], which has five levels, corresponding 
to none, slight, moderate, severe and extreme problems. 
There is strong evidence to suggest that the 5L will sup-
plant the 3L version and the Norwegian Registry for 
Spine Surgery started using the former in 2019.
Based on the findings of recent systematic reviews and 
an international panel of experts, the EQ-5D was recom-
mended for LBP [10, 11], but evidence for measurement 
properties has been deemed insufficient for widely used 
generic PROMs, including both versions of the EQ-5D 
[12]. The EQ-5D-3L has undergone limited evaluation in 
Norwegian patients with LBP [3, 13, 14] but it was con-
cluded that the instrument is reliable and has evidence 
for validity supporting its use in economic evaluation 
[3]. Just two Chinese studies have assessed the 5L version 
in LBP and it was concluded that it was appropriate and 
valid [15, 16].
Following a systematic review that included 25 reports 
of concurrent or health-to-head comparisons of the EQ-
5D-3L and 5L in diverse illness and healthy populations, 
it was found that the 5L showed similar or better meas-
urement properties [9]. Updated systematic searches of 
PubMed lend further support to this finding based on a 
further twelve concurrent evaluations of data quality and 
measurement properties including validity and respon-
siveness to change, again in diverse illness groups and the 
general population [17–30]. It is important that the 5L 
is further evaluated for measurement properties in LBP 
[12]. Concurrent evaluation alongside the 3L will inform 
the choice of which version is the most appropriate [12, 
31].
The study reported here is the first to consider the 
concurrent measurement properties of the two versions 
of the EQ-5D, administered at long-term follow-up, to 
patients with severe LBP randomized to rehabilitation or 
surgery with disc prostheses [14, 32]. The two versions 
are evaluated according to recognized measurement cri-
teria for PROMs including those that have been used in 
previous comparisons of the 3L and 5L [9, 17–30].
Methods
Data collection
The study is an 8-year follow-up of a randomized mul-
ticentre study conducted at five university hospitals 
across Norway [32]. The trial included 173 patients aged 
25–55  years randomised to rehabilitation or lumbar 
total disc replacement. Written informed consent was 
obtained and the inclusion criteria have been described 
[33]. PROMs were administered before randomization, 
and at 6 weeks, 3 months, 6 months, 1 year, 2 years and 
8 years following the trial intervention. At the eight years 
endpoint of the trial, patients received a postal question-
naire and returned it in a reply-paid envelope before their 
follow-up visit [32].
The study was approved by the Norwegian Regional 
Committee for Medical Research Ethics South East C 
(2011/2177), conducted in accordance with the Helsinki 
Declaration and the ICH-GCP guidelines.
Outcomes and psychological instruments
The eight-page self-completed questionnaire included the 
EQ-5D-3L and 5L on pages four and eight respectively. 
Health states from both versions are transformed to a 
single index using a scoring algorithm derived from valu-
ation tasks undertaken with general population samples. 
An algorithm is not yet available for Norway and hence, 
recommendations of the Norwegian Medicines Agency 
[34] were followed, including the use of the UK value set 
[35] and mapping [36]. Scores for the EQ-5D index range 
from − 0.59 to 1, where 1 is the best possible health state. 
Summated rating scale scores were also computed for 
both versions to provide further information on the con-
tribution of the additional two 5L response categories, in 
the absence of the scoring algorithm. In addition to the 
five dimensions, the EuroQol VisualAnalogue Scale (EQ 
VAS), assesses self-rated health on a vertical VAS, with 
endpoints labelled “Best imaginable health state” (100) 
and “Worst imaginable health state” (0).
The questionnaire also included the Norwegian ver-
sion 2.0 of the Oswestry Disability Index (ODI) which 
has ten items assessing pain and daily activities with 
item-specific six-point descriptive scales [37]. ODI scores 
range from 0 to 100, with a lower score indicating less 
pain and disability. The instrument has evidence for reli-
ability and validity in Norwegian patients with back pain 
[38]. Pain was assessed using visual analogue scale (VAS) 
measure of LBP ranging from 0 (no pain) to 100 (worst 
pain imaginable) relating to the back/hips and legs/feet 
[32]. Psychological distress was assessed by the Hopkin’s 
Symptom Check List (HSCL-25), which has 25 items 
assessing anxiety and depression symptoms during the 
last week [39]. Items have a four-point scale from  “not 
at all” to “to a large extent” and sum to a score from 0 
to 4, where 4 is the most severe symptoms [39, 40]. The 
instrument has been widely used in back pain research in 
Norway [8] and is considered acceptable for screening for 
depression in the Norwegian general population [40].
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Statistical analysis
Missing data and floor and ceiling effects were assessed 
for both versions of the EQ-5D. Following published 
comparisons of the 3L and 5L versions, classification 
efficiency was assessed using Shannon’s indices of H′, 
which assesses the extent to which information is evenly 
distributed across response categories, and J′, which also 
accounts for the number of response categories [9].
H′ can range from 0 to 1.58 for the 3L and 2.32 for the 5L, 
higher values indicating greater efficiency. J′ can range 
from 0 to 1, where 1 is greater efficiency with responses 
evenly distributed across categories [9].
Criteria for expected correlations between the EQ-5D 
and other instrument or item scores followed those 
included in a systematic review [12]. It has been argued 
that the EQ VAS is conceptually distinct to the EQ-5D 
index [41] but they both assess health in general, the 
latter including values for the health states assessed. 
Furthermore, if the five EQ-5D dimension scores make 
important contributions to health, then they should be 
highly correlated with the EQ-VAS scores. Hence, high 
levels of correlation ≥ 0.60 were expected between all 
aspects of the EQ-5D and the EQ VAS. However, slightly 
higher correlations were expected for the simple sum 
score of responses to the EQ-5D dimensions, because 
this does not include values for health states.
Whilst the EQ-5D is generic and the ODI relates to 
back pain, there is substantial overlap in content and 
scores for generic PROMs correlate moderate to highly 
with those specific to LBP [3, 15, 38]. Three ODI items 
(pain intensity, personal hygiene, walking) assess the 
same or very similar constructs as the EQ-5D, three 
assess aspects of usual activities (social life, sexual activ-
ity, travelling) and except for sleeping, there is consider-
able overlap for the remainder (lifting, sitting, standing). 
Except for anxiety/depression, high levels of correla-
tion ≥ 0.60 were for expected between EQ-5D scores, 
and those for the ODI. Similar levels of correlation were 
expected between the EQ-5D pain/discomfort dimen-
sion and Pain-VAS scores. The HSCL-25 assesses anxiety 
and depression and except for the corresponding EQ-5D 
dimension, for which a high level of correlation ≥ 0.60 
was expected, has very little overlap with the EQ-5D.
Correlations < 0.60 and ≥ 0.30 were expected for scores 
assessing largely related but dissimilar constructs: EQ-5D 
(index, sum, mobility, self-care, usual activities) and Pain-
VAS; EQ-5D index, sum and HSCL-25. Correlations 




J ′ = H ′/H ′max
of < 0.50 and ≥ 0.20 were expected for scores assessing 
moderately related but dissimilar constructs: EQ-5D 
dimensions (except anxiety/depression) and HSCL-25; 
EQ-5D anxiety/depression and ODI. Finally, correla-
tions < 0.30 were expected for instrument scores assessing 
weakly related or unrelated constructs: EQ-5D anxiety/
depression with Pain-VAS scores. Furthermore, given the 
performance of the 5L relative to the 3L in other popu-
lations [9, 17–30], it was hypothesized that compared to 
those for the 3L, the 5L scores would have slightly higher 
correlations.
The five EQ-5D-3L and 5L dimension scores were 
compared with ODI categories of severity [16, 37] and 
anxiety/depression scores compared with the HSCL-25 
cut-off point for diagnosis of psychiatric morbidity [40], 
by means of contingency tables and Chi-squared test. 
Finally, receiver operating characteristic curve analysis 
[42] was used to assess the discriminative ability of the 
EQ-5D-3L and 5L in discriminating between respond-
ents with minimal versus moderate or worse disability for 
the ODI scores [16, 37]. The area under the curve ranges 
from 0.5 (no discriminative ability) to 1.0 (perfect dis-
criminative ability).
Statistical analyses were undertaken using SPSS ver-




There were 151 (87%) patients available for the 8-year 
follow-up. Table  1 shows their background characteris-
tics and ODI and Pain-VAS scores. Their mean age was 
50 (SD = 7.0) years and 53% were female.
Statistical analysis
Missing data for both the 3L and 5L ranged from 1 to 2 
dimensions and the same number of index scores were 
calculable; 146 patients completed both versions of the 
EQ-5D and are included in the results that follow.
For both versions of the EQ-5D and except for pain/
discomfort, most patients reported none or slight/some 
problems across the five dimensions (Table  2). Apart 
from the self-care dimension and extreme problems, 
there were responses to all 3L response categories. For 
the 5L version, four and five of the response categories 
were used for three and two dimensions respectively. 
Floor effects (extreme problems), were very low for all 
but the pain/discomfort dimension where, compared to 
the 5L, 16% more patients had the worst level of pain 
for the 3L version. This was statistically significant. Ceil-
ing effects (no problems), ranged from 18–73% and from 
13–69% for the 3L and 5L respectively. Differences were 
statistically significant for all but the usual activities 
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dimension. The largest difference between the two ver-
sions was for the mobility dimension, where a further 
10% of patients reported no problems for the 3L. Based 
on response combinations to the five dimensions, the 
146 patients had 28 (of a possible 243) and 73 (of a pos-
sible 3,125) separate health states as assessed by the 3L 
and 5L respectively. The mean (SD) index scores were 
0.61 (0.32) and 0.66 (0.24) for the 3L and 5L respectively. 
Ceiling effects were 20 (14%) and 15 (11%) for the 3L and 
5L respectively and the difference was not statistically 
significant. There were no floor effects.
Table 3 shows response consistency. The great majority 
of patients reporting no problems for the 3L also report 
no problems for the 5L dimensions; 7–27% respond with 
slight problems on the 5L, the largest shift being for the 
pain/discomfort. The majority of patients reporting some 
problems for the 3L, report slight problems on the 5L; 
the pain dimension has a similar level of responses for 
both slight and moderate problems. Apart from the pain 
dimension, very few patients report extreme problems 
on the 3L, and the majority report severe rather than 
extreme problems on the 5L. Usual activities is the excep-
tion, where five of the six patients report extreme prob-
lems on the 5L. Between one and seven patients have 
response inconsistencies for each dimension, the high-
est being for the usual activities dimension, where six 
patients reporting some problems for the 3L report no 
problems for the 5L.
Shannon’s H’ ranged from 0.25 (self-care) to 0.40 (pain/
discomfort) and from 0.36 (self-care) to 0.61 (pain/dis-
comfort) for the 3L and 5L items respectively. J′ ranged 
from 0.12 (self-care) to 0.28 (pain/discomfort) and from 
0.17 (self-care) to 0.47 (pain/discomfort) for the 3L and 
5L items respectively. Compared to the 3L, 5L dimen-
sions showed mean information gain ranging from 1.36 
(anxiety/depression) to 1.60 (usual activities) for H′ and 
from 1.38 (anxiety/depression) to 1.70 (pain/discomfort) 
for J′.
Table 4 shows the correlations between the EQ-5D-3L 
and 5L scores and those for the other instruments. 
Table 1 Patient characteristics at eight-year follow-up for those 
completing the EQ-5D-3L and 5L (n = 146)
N % (SD)
Mean age (years) 49.9 (7.0)
Female (%) 78 53.4
Work status:
 Working 61 41.8
 Sick leave (100%) 10 6.9
 Student 1 0.7
 Sick leave (< 100%) 4 2.7
 Pension 1 0.7
 In rehabilitation 18 12.3
 Disability pension 50 34.2
 Unemployed 1 0.7
Mean ODI 8-year follow-up 24.75 (16.11)
ODI minimal disability (0–20) 61 41.8
ODI moderate disability (21–40) 62 42.5
ODI severe disability (41–60) 21 14.4
ODI crippling back pain (60–80) 2 1.4
ODI bed-bound (80–100) 0 0
Mean VAS-pain 8-year follow-up 42.10 (26.67)
Table 2 Response frequencies (%) for the EQ-5D-3L and 5L (n = 146)
Asterisks denote statistically significant differences for McNemar’s related-samples change test: *P < 0.05; **P < 0.01
EQ-5D-3L No problems Some problems Extreme 
problems/
unable to do
Mobility 92 (63.0) 52 (35.6) 2 (1.4)
Self-care 107 (73.3) 39 (26.7) 0 (0.0)
Usual activities 48 (32.9) 92 (63.0) 6 (4.1)
Pain/discomfort 26 (17.8) 92 (63.0) 28 (19.2)
Anxiety/depression 94 (64.4) 50 (34.2) 2 (1.4)
EQ-5D-5L No problems Slight problems Moderate problems Severe problems Extreme 
problems/
unable to do
Mobility 77 (52.7)** 42 (28.8) 21 (14.4) 6 (4.1) 0 (0.0)
Self-care 100 (68.5)* 37 (25.3) 5 (3.4) 4 (2.7) 0 (0.0)
Usual activities 46 (31.5) 68 (46.6) 19 (13.0) 8 (5.5) 5 (3.4)
Pain/discomfort 19 (13.0)* 52 (35.6) 43 (29.5) 28 (19.2) 4 (2.7)**
Anxiety/depression 85 (58.2)** 45 (30.8) 14 (9.6) 2 (1.4) 0 (0.0)
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Compared to the 3L, 5L dimension, sum and index scores 
had slightly higher correlations with those for the EQ 
VAS. For both versions, the highest correlations with 
ODI scores were found for the pain/discomfort dimen-
sion followed by correlations ≥ 0.60 for all but anxiety/
depression. The pain/discomfort dimension had the 
highest correlations of 0.66–0.82, with the two Pain-VAS 
scores. Apart from anxiety/depression, correlations with 
Pain-VAS scores were higher than expected. Correlations 
with the HSCL-25 were ≥ 0.60 for anxiety/depression, 
Table 3 Response consistency (%) between the EQ-5D-5L and EQ-5D-3L (n = 146)
Inconsistencies are marked in bold
EQ-5D-3L EQ-5D-5L
No problems Slight problems Moderate problems Severe problems Unable/extreme
Mobility
 No problems (n = 92) 77 (83.7) 14 (15.2) 1 (1.1) 0 (0.0) 0 (0.0)
 Some problems (n = 52) 0 (0.0) 28 (53.8) 20 (38.5) 4 (7.7) 0 (0.0)
 Unable/extreme (n = 2) 0 (0.0) 0 (0.0) 0 (0.0) 2 (100.0) 0 (0.0)
Self-care
 No problems (n = 107) 99 (92.5) 8 (7.5) 0 (0.0) 0 (0.0) 0 (0.0)
 Some problems (n = 39) 1 (2.6) 29 (74.4) 5 (12.8) 4 (10.3) 0 (0.0)
 Unable/extreme(n = 0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Usual activities
 No problems (n = 48) 40 (83.3) 8 (16.7) 0 (0.0) 0 (0.0) 0 (0.0)
 Some problems (n = 92) 6 (6.5) 60 (65.2) 18 (19.6) 8 (8.7) 0 (0.0)
 Unable/extreme (n = 6) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 5 (83.3)
Pain/discomfort
 No problems (n = 26) 19 (73.1) 7 (26.9) 0 (0.0) 0 (0.0) 0 (0.0)
 Some problems (n = 92) 0 (0.0) 45 (48.9) 41 (44.6) 6 (6.5) 0 (0.0)
 Unable/extreme (n = 28) 0 (0.0) 0 (0.0) 2 (7.1) 22 (78.6) 4 (14.3)
Anxiety/depression
 No problems (n = 94) 85 (90.4) 9 (9.6) 0 (0.0) 0 (0.0) 0 (0.0)
 Some problems (n = 50) 0 (0.0) 36 (72.0) 13 (26.0) 1 (2.0) 0 (0.0)
 Unable/extreme (n = 2) 0 (0.0) 0 (0.0) 1 (50.0) 1 (50.0) 0 (0.0)
Table 4 Listwise Spearman  correlationsa (n = 146)
a All correlations are statistically significant (P < 0.01) unless indicated: NS not significant. Scores are coded in the same direction to ease interpretation
b EQ-5D-3L and 5L index are based on recommended scoring, whereas the sum scores are the sum of the scores for the five dimensions
EQ VAS Oswestry Disability Index Pain-VAS Back/Hips Pain-VAS Legs/feet HSCL-25
EQ-5D-3L index 0.72 0.84 0.76 0.64 0.65
EQ-5D-3L  sumb 0.76 0.87 0.77 0.66 0.66
 Mobility 0.57 0.68 0.57 0.61 0.41
 Self-care 0.56 0.65 0.59 0.46 0.37
 Usual activities 0.65 0.72 0.65 0.49 0.51
 Pain/discomfort 0.62 0.77 0.75 0.66 0.45
 Anxiety/depression 0.39 0.36 0.26 0.19NS 0.64
EQ-5D-5L index 0.74 0.87 0.82 0.70 0.68
EQ-5D-5L sum 0.77 0.88 0.80 0.69 0.69
 Mobility 0.59 0.72 0.62 0.60 0.45
 Self-care 0.56 0.66 0.62 0.48 0.46
 Usual activities 0.73 0.75 0.68 0.57 0.54
 Pain/discomfort 0.68 0.85 0.82 0.76 0.51
 Anxiety/depression 0.40 0.41 0.31 0.17NS 0.72
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otherwise mostly < 0.50 for other dimensions. The two 
index scores had correlations ≥ 0.60 with those for other 
instruments. The EQ-5D-5L had slightly higher cor-
relations than the 3L with other instrument scores; the 
largest of up to 0.10 were for the pain/discomfort dimen-
sion. Compared to the index scores, EQ-5D sum scores 
had slightly higher correlations with those for the other 
instruments, except for the two Pain-VAS scales and the 
5L.
Table 5 shows responses to the EQ-5D dimensions by 
ODI categories of severity and anxiety/depression by 
HSCL-25 cut-off for psychiatric diagnosis. Compared to 
the 3L, more response categories were used for the 5L 
across ODI severity levels and particularly for moderate 
and severe levels. For both versions, there was the same 
number of respondents below the HSCL-25 cut-off. For 
those at or above the cut-off, there was a greater spread 
of 5L responses compared to the 3L. Chi-squared values 
were consistently higher for the 5L. Both EQ-5D-3L and 
5L index scores were statistically significant in discrimi-
nating between respondents with ODI scores indicating 
minimal and higher levels of severity. The area under the 
curve (95% CI) for the 3L and 5L was 0.946 (0.914–0.977) 
and 0.956 (0.928–0.984) respectively. The results were 
very similar for the EQ-5D sum scores.
Discussion
The concurrent nature of this study represents the 
strongest available evidence for choosing the most recent 
version of the EQ-5D with five levels in LBP research 
and other forms of application. Levels of missing data 
were similar for both versions and low. Across EQ-5D-5L 
dimensions, patients used four or five response categories 
and hence described a greater range of health states than 
for the 3L (73 versus 28). There was a significantly higher 
floor effect for the pain/discomfort dimension for the 3L 
version, an important aspect of health in these patients. 
Ceiling effects were large across both instruments, which 
was expected in this long-term follow-up of patients [32]. 
There was little difference between the two versions for 
the usual activities dimension, but for the remaining four 
dimensions there were statistically significant differences 
in favour of the 5L.
One systematic review that included comparisons of 
the two versions in various illness groups and the general 
population [9], also found low levels of missing data for 
both versions, and that using the 5L could reduce ceiling 
effects by up to 17% for mobility and 30% for self-care 
dimensions. Floor effects were found to be largely below 
5% across dimensions, but in common with the findings 
reported here, the largest reduction from using the 5L 
was found for pain/discomfort [9]. The review included 
patient populations that were not part of a long-term 
follow-up and hence larger differences in ceiling effects 
might be expected compared to the results reported here. 
More recent comparisons across diverse illness groups 
have found statistically significant reductions in ceiling 
effects for the 5L relative to the 3L [22, 24–26, 28], with 
the pain/discomfort dimension often being the largest 
and ranging from 5 to 17% for Crohn’s disease [22] and 
older people with moderate to high levels of comorbidity 
[25] respectively.
The assessment of response consistency was limited 
because very few patients scored at the floor or the poor-
est level of health for both versions. The few inconsist-
encies were magnified by the small samples available. 
Shannon’s indices also showed that the 5L outperformed 
the 3L in tests of classification efficiency which was found 
in previous studies [17, 18, 21–26, 29].
The inclusion of the ODI, Pain-VAS and HSCL-25 in 
correlations based on bypothesis testing, follows exist-
ing LBP studies [3, 8, 12, 13, 38], and hence, was impor-
tant for assessing the comparative performance of the 
EQ-5D-3L and 5L. Compared to the 3L, the 5L index 
and dimension scores had higher levels of correlation 
with those for these instruments and were more highly 
associated with ODI and HSCL-25 levels of severity. The 
largest differences were for the pain/discomfort dimen-
sion, which reflects the content of the ODI, Pain-VAS 
items and their specific focus on LBP. Together, the find-
ings show that the EQ-5D assesses important aspect of 
health in LBP, and that the 5L improves upon the 3L in 
this respect. The findings of a recent systematic review 
highlighted the need for further testing for the construct 
validity of the EQ-5D-5L in LBP patients [12]. Two Chi-
nese studies  have since concluded that the 5L has evi-
dence for validity in these patients [15, 16]. Compared 
to the findings reported here, slightly lower levels of cor-
relation with the ODI were reported in a sample of out-
patients [15]. In a sample that also included in-patients, 
higher AUC scores were found for the EQ-5D-5L com-
pared to the SF-6D, and in relation to the ODI severity 
categories reported here [16].
Study strengths and limitations
The EQ-5D-5L was not available when the randomized 
trial began [32], which constrained the study design and 
measurement properties tested. Study strengths include 
the concurrent nature of the evaluation which gives the 
strongest available evidence for comparative measure-
ment performance [9, 12, 31]. However, the ordering of 
two versions of the EQ-5D may have affected results. The 
study was part of an eight-year follow-up of a randomized 
trial which defined the questionnaire layout and ordering 
of the PROMs. Had the study been primarily concerned 
with comparing the EQ-5D-5L and EQ-5D-3L, then 
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Table 5 EQ-5D  responsesa (%) for ODI and HSCL-25 severity levels (n = 146)
a Response categories not included where there were no responses
b All results are statistically significant: p < 0.001
ODI classification
Minimal Moderate Severe/crippling Chi-squareb
EQ-5D-3L
 Mobility No problems 59 (40.4) 31 (21.2) 2 (1.4) 69.90
Some problems 2 (1.4) 31 (21.2) 19 (13.0)
Unable/extreme – – 2 (1.4)
 Self-care No problems 61 (41.8) 43 (29.5) 3 (2.1) 65.36
Some problems – 19 (13.0) 20 (13.7)
 Usual activities No problems 43 (29.4) 5 (3.4) – 71.14
Some problems 18 (12.3) 54 (37.0) 20 (13.7)
Unable/extreme – 3 (2.1) 3 (2.1)
 Pain/discomfort No problems 26 (17.8) – – 92.85
Some problems 35 (24.0) 51 (34.9) 6 (4.1)
Unable/extreme – 11 (7.5) 17 (11.6)
 Anxiety/depression No problems 50 (34.2) 37 (25.3) 7 (4.8) 22.42
Some problems 10 (6.8) 25 (17.1) 15 (10.3)
Unable/extreme 1 (0.7) – 1 (0.7)
EQ-5D-5L
 Mobility No problems 57 (39.0) 19 (13.0) 1 (0.7) 99.84
Slight problems 3 (2.1) 32 (21.9) 7 (4.8)
Moderate problems 1 (0.7) 10 (6.8) 10 (6.8)
Severe problems – 1 (0.7) 5 (3.4)
 Self-care No problems 60 (41.1) 36 (24.7) 4 (2.7) 78.48
Slight problems 1 (0.7) 25 (17.1) 11 (7.5)
Moderate problems – 1 (0.7) 4 (2.7)
Severe problems – – 4 (2.7)
 Usual activities No problems 41 (28.1) 5 (3.4) – 85.43
Slight problems 19 (13.0) 41 (28.1) 8 (5.5)
Moderate problems 1 (0.7) 10 (6.8) 8 (5.5)
Severe problems – 3 (2.1) 5 (3.4)
Unable/extreme – 3 (2.1) 2 (1.4)
 Pain/discomfort No problems 19 (13.0) – – 125.34
Slight problems 36 (24.7) 16 (11.0) –
Moderate problems 6 (4.1) 33 (22.6) 4 (2.7)
Severe problems – 13 (8.9) 15 (10.3)
Unable/extreme – – 4 (2.7)
 Anxiety/depression No problems 48 (32.9) 31 (21.2) 6 (4.1) 27.75
Slight problems 10 (6.8) 25 (17.1) 10 (6.8)
Moderate problems 2 (1.4) 6 (4.1) 6 (4.1)
Severe problems 1 (0.7) – 1 (0.7)
EQ-5D-3L HSCL-25 < 1.75 HSCL-25 ≥ 1.75
 Anxiety/ depression No problems 77 (54.6) 15 (10.6) 40.15
Slight problems 15 (10.6) 33 (23.4)
Unable/extreme – 1 (0.7)
EQ-5D-5L
 Anxiety/ depression No problems 72 (51.1) 11 (7.8) 51.74
Slight problems 20 (14.2) 23 (16.3)
Moderate problems – 13 (9.2)
Severe problems – 2 (1.4)
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randomizing patients to two questionnaires, one with the 
5L and one with the 3L, would have been the preferred 
design. This would also have alleviated any concerns 
that completing the 3L prior to the 5L might have influ-
enced responses to the latter. The 3L came first because 
it was used at baseline, and hence was an important out-
come measure within the trial. There is no way of testing 
for such potential biases within the current design. The 
questionnaire was brief with eight pages of A4 and hence 
there is limited grounds to expect that respondent bur-
den may have contributed to the 5L version performing 
poorer relative to the 3L version.
The longitudinal nature of the main study also limited 
the measurement properties that could be tested and 
previously reported for the EQ-5D-3L in LBP patients, 
including reliability and responsiveness to change [3, 12, 
14]. Furthermore, the design precluded estimating the 
standard error of measurement and minimal detectable 
change. It is recommended that these measurement cri-
teria are considered in future testing of the EQ-5D-5L in 
LBP patient populations. The current findings, together 
with those from other studies that included LBP patients 
[15, 16] and other populations [9, 17–30], indicate that 
the results of further testing for measurement properties 
including responsiveness to change, will favour the 5L.
There is currently no Norwegian value set or scor-
ing algorithm for the EQ-5D-5L. Norwegian data was 
being collected for this purpose [43] but was postponed 
because of the COVID-19 pandemic. In the absence of a 
Norwegian scoring algorithm, scoring of the EQ-5D-3L 
and 5L index followed existing recommendations [34]. 
The analyses undertaken here should be replicated for the 
EQ-5D-5L index when a Norwegian EQ-5D value set and 
scoring algorithm become available. Norwegian medical 
registers including the National Register for Spine Sur-
gery [4], recently supplanted the 3L with the 5L, and the 
findings here support the national recommendations [34] 
that they follow.
Conclusions
The EQ-5D is the most widely used short generic instru-
ment suitable for use in economic evaluation including 
cost per QALY calculations. These results support the 
use of the 5L in preference to the 3L version but further 
and more extensive testing in other LBP populations is 
recommended.
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